Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An indolent, mature B-cell neoplasm composed of small, round B-lymphocytes. When the bone marrow and peripheral blood are involved, the term chronic lymphocytic leukemia is used. The term small lymphocytic lymphoma is restricted to cases which do not show leukemic involvement of the bone marrow and peripheral blood.
Biomarker and diagnostic research for chronic lymphocytic leukemia/small lymphocytic lymphoma has been reported in the published literature.
2 FDA-approved treatments are available for chronic lymphocytic leukemia/small lymphocytic lymphoma, including BENDAMUSTINE HYDROCHLORIDE (BENDAMUSTINE HYDROCHLORIDE, approved 2022) and PIRTOBRUTINIB (JAYPIRCA, approved 2023). An additional 3 compounds hold orphan drug designation.
Brand Name | Generic Name | Mechanism | Approved |
|---|
55 clinical trials registered, 22 recruiting. Interventions under study include drug therapy, biologic therapy, procedural interventions, and other interventions. Pipeline includes 2 PHASE4, 13 PHASE3, 25 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05602363](https://clinicaltrials.gov/study/NCT05602363) |
Data assembled from 4 of 12 sources · Last updated Nov 4, 2026, 6:14 AM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
JAYPIRCA | PIRTOBRUTINIB | — | 2023 | Available |
BENDAMUSTINE HYDROCHLORIDE | BENDAMUSTINE HYDROCHLORIDE | — | 2022 | Available |
The following drugs have received orphan drug designation from the FDA for chronic lymphocytic leukemia/small lymphocytic lymphoma. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor | Designated | Exclusivity End | Designation Status |
|---|---|---|---|---|---|
copanlisib | copanlisib | Bayer HealthCare Pharmaceuticals Inc. | 2021 | — | Withdrawn |
cirmtuzumab | cirmtuzumab | Ho’ola Therapeutics Inc. | 2020 | — | Designated |
N-[5-(6-fluoro-8-{[4-(2-hydroxypropan-2-yl) piperidin-1-yl]methyl}-2-morpholinoquinazolin-4-yl)-2-methoxypyridin-3-]methanesulfonamide | N-[5-(6-fluoro-8-{[4-(2-hydroxypropan-2-yl) piperidin-1-yl]methyl}-2-morpholinoquinazolin-4-yl)-2-methoxypyridin-3-]methanesulfonamide | Shanghai Yingli Pharmaceutical Co., Ltd. | 2018 | — | Designated |
Gene therapy approaches for chronic lymphocytic leukemia/small lymphocytic lymphoma have been reported in the published literature.
55 trials found
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma |
PHASE1 |
Carna Biosciences, Inc. |
RECRUITING |
[NCT06943872](https://clinicaltrials.gov/study/NCT06943872) | A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) | PHASE3 | BeOne Medicines | RECRUITING |
[NCT05947851](https://clinicaltrials.gov/study/NCT05947851) | A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). | PHASE3 | Merck Sharp & Dohme LLC | RECRUITING |
[NCT06319456](https://clinicaltrials.gov/study/NCT06319456) | A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. | PHASE3 | Ascentage Pharma Group Inc. | RECRUITING |
[NCT06508684](https://clinicaltrials.gov/study/NCT06508684) | Current Status of BTKi Treatment for CLL/SLL in China | — | The First Affiliated Hospital with Nanjing Medical University | RECRUITING |
184 publications have been identified in PubMed for chronic lymphocytic leukemia/small lymphocytic lymphoma. Research spans Review / Meta-Analysis (24%), Case Report / Case Series (22%), and Epidemiology / Natural History (22%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 44 | 24% |
Patient case studies | 41 | 22% |
Disease patterns and progression | 40 | 22% |
Clinical study results | 35 | 19% |
Other research | 9 | 5% |
Testing and diagnosis research | 7 | 4% |
Laboratory research | 4 | 2% |
New treatment approaches | 4 | 2% |
Pinilla-Ibarz J (2026). [PMID: 41662512](https://pubmed.ncbi.nlm.nih.gov/41662512/). *Expert Rev Hematol*. [Epidemiology / Natural History]
Woyach JA (2026). [PMID: 41353787](https://pubmed.ncbi.nlm.nih.gov/41353787/). *J Clin Oncol*. [Clinical Trial Publication]
Jurczak W (2026). [PMID: 41363773](https://pubmed.ncbi.nlm.nih.gov/41363773/). *J Clin Oncol*. [Clinical Trial Publication]
Wierda WG (2026). [PMID: 41825137](https://pubmed.ncbi.nlm.nih.gov/41825137/). *J Natl Compr Canc Netw*. [Review / Meta-Analysis]
Tidswell R (2026). [PMID: 41698679](https://pubmed.ncbi.nlm.nih.gov/41698679/). *Eur J Haematol*. [Epidemiology / Natural History]
D'Amato M (2026). [PMID: 41793543](https://pubmed.ncbi.nlm.nih.gov/41793543/). *Clin Exp Med*. [Review / Meta-Analysis]
Ghosh N (2026). [PMID: 41529988](https://pubmed.ncbi.nlm.nih.gov/41529988/). *Clin Lymphoma Myeloma Leuk*. [Review / Meta-Analysis]
Slater VE (2026). [PMID: 42066411](https://pubmed.ncbi.nlm.nih.gov/42066411/). *Leuk Res*. [Diagnostic / Biomarker]
Sun M (2026). [PMID: 42000210](https://pubmed.ncbi.nlm.nih.gov/42000210/). *Clin Lymphoma Myeloma Leuk*. [Clinical Trial Publication]
Allan JN (2026). [PMID: 41627367](https://pubmed.ncbi.nlm.nih.gov/41627367/). *Adv Ther*. [Review / Meta-Analysis]
AI-curated news mentioning chronic lymphocytic leukemia/small lymphocytic lymphoma
Updated Oct 18, 2026
A case report highlights a novel BCL2 translocation alongside a chromosome 13q14 deletion in a patient with chronic lymphocytic leukemia. This discovery may provide insights into the genetic underpinnings of the disease.
Recent discussions highlighted barriers to precision care, including financial toxicity from continuous BTK inhibitor therapy and the complexities of outpatient drug administration under 340B pricing. The tension between high drug costs and payment structures is impacting access to treatments for conditions like chronic lymphocytic leukemia and diabetic macular edema.
A case study highlights pulmonary light chain deposition disease in a patient with chronic lymphocytic leukemia, providing insights into the relationship between these conditions. This research contributes to understanding the complexities of rare diseases associated with hematological malignancies.
NICE has approved new combination regimens involving Acalabrutinib for chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). This decision enhances treatment options for patients with these blood cancers.
Recent research focuses on the microenvironment of chronic lymphocytic leukemia (CLL) using multi-omics approaches. This study aims to enhance understanding of CLL pathology and potential therapeutic targets.